MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199

Targeted therapies designed to exploit specific molecular pathways in aggressive cancers are an exciting area of current research. Mixed Lineage Leukemia (MLL) mutations such as the t(4;11) translocation cause aggressive leukemias that are refractory to conventional treatment. The t(4;11) translocat...

Descripción completa

Detalles Bibliográficos
Autores principales: Benito, Juliana M., Godfrey, Laura, Kojima, Kensuke, Hogdal, Leah, Wunderlich, Mark, Geng, Huimin, Marzo, Isabel, Harutyunyan, Karine G., Golfman, Leonard, North, Phillip, Kerry, Jon, Ballabio, Erica, Chonghaile, Triona Ní, Gonzalo, Oscar, Qiu, Yihua, Jeremias, Irmela, Debose, LaKiesha, O’Brien, Eric, Ma, Helen, Zhou, Ping, Jacamo, Rodrigo, Park, Eugene, Coombes, Kevin R., Zhang, Nianxiang, Thomas, Deborah A., O’Brien, Susan, Kantarjian, Hagop M., Leverson, Joel D., Kornblau, Steven M., Andreeff, Michael, Müschen, Markus, Zweidler-McKay, Patrick A., Mulloy, James C., Letai, Anthony, Milne, Thomas A., Konopleva, Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700051/
https://www.ncbi.nlm.nih.gov/pubmed/26711339
http://dx.doi.org/10.1016/j.celrep.2015.12.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700051/
https://www.ncbi.nlm.nih.gov/pubmed/26711339
http://dx.doi.org/10.1016/j.celrep.2015.12.003

Ejemplares similares